The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2012Lead Optimization for a Parkinson's Disease Therapeutic
Objective/Rationale:
CuII(atsm) has the potential to delay disease progression in Parkinson’s disease, based on extensive pre-clinical model data. CuII(atsm) has been shown to significantly improve... -
Clinical Intervention Awards, 2007The PARKFIT Study: Effectiveness of an Active Lifestyle Promotion Program for Patients with Parkinson’s disease
Objective/Rationale:
Parkinson's patients are inclined toward a sedentary lifestyle. This is due to a combination of both physical handicaps (e.g. walking difficulties) and mential impairments (e.g... -
Critical Challenges in PD: Alpha-synuclein Neuroimaging, 2009Utility of the Amyloid Ligand [18F]FDDNP in Human PET Imaging in Parkinson Disease
Objective/Rationale:
Biomarkers of Parkinson disease are sorely needed for the assessment of disease status so that they may be used to design more efficient and informative clinical trials of disease... -
Rapid Response Innovation Awards, 2007Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease
Objective/Rationale:
The objective of this study is to explore the effects of methylphenidate on the gait of patients with Parkinson’s disease who are experiencing shuffling and freezing... -
PD Subtypes, 2007Do Clinical Characteristics at PD Diagnosis Predict Survival?
Tremendous efforts have been directed toward the identification of factors that affect the progression of Parkinson's disease, yet to date few factors have been identified. Most studies seeking to...
-
Resource: Utilizing DATATOP Biospecimens, 2011Validation of Alpha-synuclein Oligomers as Biomarker for Parkinson’s Disease
Objective/Rationale:
We have reported recently higher levels of α-synuclein oligomers species in cerebral spinal fluid (CSF) from patients clinically diagnosed with Parkinson’s disease (PD) versus...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.